All In Biotech

Drug Trial Radar · NCT06494111

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

295

Planned (sponsor's estimate)

Start

Feb 13, 2025

Primary completion

May 1, 2029

Study completion Mar 1, 2031

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.

Conditions

  • Lymphedema
  • Fibrosis

Interventions

  • PravastatinDrug

    Given by PO

  • PentoxifyllineDrug

    Given by PO

  • TocopherolDrug

    Given by PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.